← Back to Search

Vasodilator

Papaverine + SBRT for Non-Small Cell Lung Cancer

Phase 1

Waitlist Available

Led By Jeremy Brownstein, MD

Research Sponsored by Ohio State University Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 12 and 24 months after stereotactic body radiation therapy (sbrt) completion

Awards & highlights

Study Summary

This trial studies the side effects of papaverine hydrochloride and stereotactic radiation therapy in treating patients with non-small cell lung cancer.

Eligible Conditions

Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 12 and 24 months after stereotactic body radiation therapy (sbrt) completion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 12 and 24 months after stereotactic body radiation therapy (sbrt) completion

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 12 and 24 months after stereotactic body radiation therapy (sbrt) completion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum-tolerated dose (MTD)

Secondary outcome measures

Change in hypoxia-inducible micro ribonucleic acids (miRNAs)

Changes in magnetic resonance imaging (MRI) blood oxygen level-dependent (BOLD) response

Disease

+5 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (BOLD fMRI, papaverine hydrochloride, SBRT)Experimental Treatment3 Interventions

Patients undergo BOLD fMRI and receive papaverine hydrochloride IV on day 1. Within 30-90 minutes, patients undergo a second BOLD fMRI. Patients then receive papaverine hydrochloride IV and within 30-90 minutes after dose undergo SBRT for a up to 4-5 sessions over 2 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Stereotactic Body Radiation Therapy

2012

Completed Phase 2

~780

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor

320 Previous Clinical Trials

290,143 Total Patients Enrolled

Jeremy Brownstein, MDPrincipal Investigator - Ohio State University Comprehensive Cancer Center

Ohio State University Comprehensive Cancer Center

Media Library

Papaverine Hydrochloride (Vasodilator) Clinical Trial Eligibility Overview. Trial Name: NCT03824327 — Phase 1

Non-Small Cell Lung Cancer Research Study Groups: Treatment (BOLD fMRI, papaverine hydrochloride, SBRT)

Non-Small Cell Lung Cancer Clinical Trial 2023: Papaverine Hydrochloride Highlights & Side Effects. Trial Name: NCT03824327 — Phase 1

Papaverine Hydrochloride (Vasodilator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03824327 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Papaverine Hydrochloride capable of providing risk-free relief?

"Our team has judged Papaverine Hydrochloride to be a 1 on the safety scale, as it is currently in its first phase of clinical trial and thus has limited data backing up its efficacy and safety."

Answered by AI

How large is the cohort of participants prescribed to this clinical trial?

"Affirmative, the information on clinicaltrials.gov confirms that this research study is currently recruiting patients. It was originally posted in February of 2019 and most recently updated in June of 2022. The team behind it seeks to enrol 24 individuals from a single medical facility."

Answered by AI

Could you detail any other experiments that have been conducted with Papaverine Hydrochloride?

"Currently, there are two clinical trials underway for Papaverine Hydrochloride. Unfortunately, neither of these studies have reached the final phase 3 trial stage yet. These medical tests are mainly based in Columbus, Ohio but span over 2 seperate locations."

Answered by AI

Are there any remaining openings to join this experiment?

"According to clinicaltrials.gov, the trial is currently recruiting for participants with a posted date of February 7th 2019 and an updated date of June 9 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

Jeremy Brownstein 2019. "Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03824327.